AllianceBernstein
RUBY

AllianceBernstein’s Rubius Therapeutics, Inc RUBY Stock Holding History

AllianceBernstein’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-60,200
Closed -$332K – 3443
2022
Q1 		$332K Buy
60,200
+200
+0.3% +$1.27K ﹤0.01% 2841
2021
Q4 		$581K Hold
60,000
– – ﹤0.01% 2667
2021
Q3 		$1.07M Sell
60,000
-3,100
-5% -$67.4K ﹤0.01% 2469
2021
Q2 		$1.54M Buy
63,100
+3,900
+7% +$97.5K ﹤0.01% 2332
2021
Q1 		$1.57M Sell
59,200
-18,800
-24% -$275K ﹤0.01% 2217
2020
Q4 		$592K Sell
78,000
-3,200
-4% -$19K ﹤0.01% 2514
2020
Q3 		$407K Sell
81,200
-2,100
-3% -$11.1K ﹤0.01% 2641
2020
Q2 		$498K Buy
83,300
+14,100
+20% +$83.2K ﹤0.01% 2614
2020
Q1 		$308K Buy
69,200
+23,700
+52% +$176K ﹤0.01% 2608
2019
Q4 		$432K Sell
45,500
-2,769,072
-98% -$26.8M ﹤0.01% 2601
2019
Q3 		$22.1M Buy
2,814,572
+302,120
+12% +$3.52M 0.01% 755
2019
Q2 		$39.5M Buy
2,512,452
+11,438
+0.5% +$185K 0.02% 606
2019
Q1 		$45.3M Buy
2,501,014
+216,967
+9% +$3.33M 0.03% 551
2018
Q4 		$36.7M Buy
2,284,047
+657,192
+40% +$12M 0.03% 571
2018
Q3 		$39M Buy
+1,626,855
New +$37.2M 0.03% 605

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's RUBY Position: Q2 2022 in Review

AllianceBernstein sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 60,200 shares — an estimated $332K sold.

AllianceBernstein first reported a position in RUBY in Q3 2018 and held it in 15 quarters. The position peaked at $45.3M in Q1 2019. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • AllianceBernstein reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • AllianceBernstein sold 60,200 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $332K.
  • AllianceBernstein first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 15 quarters.
  • AllianceBernstein's Rubius Therapeutics, Inc position peaked at $45.3M in Q1 2019.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.